var data={"title":"Dimercaptosuccinic acid (succimer): Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Dimercaptosuccinic acid (succimer): Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6991?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=dimercaptosuccinic-acid-succimer-patient-drug-information\" class=\"drug drug_patient\">see &quot;Dimercaptosuccinic acid (succimer): Patient drug information&quot;</a> and <a href=\"topic.htm?path=dimercaptosuccinic-acid-succimer-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Dimercaptosuccinic acid (succimer): Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F223371\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Chemet</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F223372\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Chemet</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F223387\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antidote</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F223374\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Lead poisoning (off-label use; Kosnett, 2007):</b> For the treatment of high blood lead levels in adults, chelation therapy is recommended with blood lead levels &gt;50 mcg/dL and significant symptoms; chelation therapy may also be indicated with blood lead levels &ge;100 mcg/dL and/or symptoms.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral: Consider  using labeled dose for children: 10 mg/kg/dose (or 350 mg/m<sup>2</sup>/dose) every 8 hours for 5 days, followed by 10 mg/kg/dose (or 350 mg/m<sup>2</sup>/dose) every 12 hours for 14 days; Maximum: 500 mg/dose.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Note:</b> Treatment courses may be repeated, but 2-week intervals between courses is generally recommended.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F223383\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=dimercaptosuccinic-acid-succimer-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Dimercaptosuccinic acid (succimer): Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Lead poisoning:</b> For the treatment of high blood lead levels in children, the CDC recommends chelation treatment when blood lead levels are &gt;45 mcg/dL (CDC, 2002). Children with blood lead levels &gt;70 mcg/dL or symptomatic lead poisoning should be treated with parenteral agents (AAP, 2005).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral: 10 mg/kg/dose (or 350 mg/m<sup>2</sup>/dose) every 8 hours for 5 days followed by 10 mg/kg/dose (or 350 mg/m<sup>2</sup>/dose) every 12 hours for 14 days. Maximum: 500 mg/dose.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Note:</b> Treatment courses may be repeated, but 2-week intervals between courses is generally recommended.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F223375\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F223376\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\"> No dosage adjustment provided in the manufacturer&rsquo;s labeling; use with caution. Succimer is dialyzable; however, the lead chelates are not.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F223377\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">No dosage adjustment provided in the manufacturer&rsquo;s labeling; has not been studied. More frequent monitoring of serum transaminases may be required in patients with a history of liver disease due to the risk of transient increases. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20989270\" class=\"block dot drugH1Div\"><span class=\"drugH1\">Dosing: Adjustment for Toxicity</span>\n    <p style=\"text-indent:0em;display:inline\">ANC &lt;1200 mm<sup>3</sup>:  The manufacturer recommends withholding treatment; treatment may be cautiously resumed when ANC returns to baseline or &gt;1500/mm<sup>3</sup>. Consultation with a medical toxicologist to determine the risk versus benefit of withholding treatment is recommended.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F223356\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Capsule, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Chemet: 100 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F223342\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5168980\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">If unable to swallow whole, capsule may be separated and contents sprinkled on a small amount of soft food, or the contents placed on a spoon and administered followed by fruit drink.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F223357\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\"> Treatment of lead poisoning in children with serum lead levels &gt;45 mcg/dL </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25470676\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Lead poisoning (Adults)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F223348\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Metallic taste</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Decreased appetite, diarrhea, hemorrhoids, loose stools, nausea, vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Cardiac arrhythmia (adults: 2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Chills, dizziness, drowsiness, fatigue, flank pain, headache, neuropathy, paresthesia</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Skin rash (including herpetic lesion, mucocutaneous eruptions, papular rash), pruritus</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Increased serum cholesterol</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Abdominal cramps, mucositis, sore throat</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Genitourinary: Decreased urine output (adults), difficulty in micturition (adults), proteinuria (adults)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Change in platelet count (increase), eosinophilia</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hepatic: Increased serum alkaline phosphatase, increased serum ALT, increased serum AST</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infection: Candidiasis, common cold</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Back pain, knee pain (adults), leg pain (adults), rib pain</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Ophthalmic: Cloudy vision (cloudy film in eye), watery eyes</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Otic: Blocked ear, otitis media</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Cough, flu-like symptoms, nasal congestion, rhinorrhea</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Miscellaneous: Fever</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Hypersensitivity reaction (especially with retreatment), neutropenia (causal relationship not established)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F223361\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to succimer or any component of the formulation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F223346\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hematologic effects: Mild-to-moderate neutropenia has been reported; evaluate CBC with differential at baseline, weekly during treatment, and immediately upon the development of any sign of infection.  The manufacturer recommends withholding treatment for ANC &lt;1200/mm<sup>3</sup>; treatment may be cautiously resumed when ANC returns to baseline or &gt;1500/mm<sup>3</sup>. Consultation with a medical toxicologist to determine the risk versus benefit of withholding treatment is recommended.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hepatic effects: Transient elevations in serum transaminases have been reported. Evaluate serum transaminases at baseline and weekly during treatment; more frequent monitoring may be required in patients with a history of liver disease.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hypersensitivity reactions: Monitor for the development of allergic or other mucocutaneous reactions. A reversible mucocutaneous vesicular eruption of the oral mucosa, external urethral meatus, or perianal area has been reported (rarely).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Encephalopathy:  Succimer does not cross blood-brain barrier and should not be used to treat encephalopathy associated with lead toxicity.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Lead poisoning: Investigate, identify, and remove sources of lead exposure prior to treatment; do not permit patients to re-enter the contaminated environment until lead abatement has been completed. Primary care providers should consult experts in chemotherapy of heavy metal toxicity before using chelation drug therapy. Succimer is not used to prevent lead poisoning. A rebound rise in serum lead levels may occur after treatment as lead is released from storage sites into blood. The severity of rebound may guide the frequency of future monitoring and the need for additional chelation therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Renal impairment: Use with caution in patients with renal impairment. Succimer is dialyzable; however, the lead chelates are not.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hydration: Adequate hydration should be maintained during therapy.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13300085\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6223110\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9102&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:0em;display:inline\">There are no known significant interactions.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F223352\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6165840\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events were observed in animal reproduction studies.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Lead poisoning: Lead is known to cross the placenta in amounts related to maternal plasma levels. Prenatal lead exposure may be associated with adverse events such as spontaneous abortion, preterm delivery, decreased birth weight, and impaired neurodevelopment. Some adverse outcomes may occur with maternal blood lead levels &lt;10 mcg/dL. In addition, pregnant women exposed to lead may have an increased risk of gestational hypertension. Consider chelation therapy in pregnant women with confirmed blood lead levels &ge;45 mcg/dL (pregnant women with blood lead levels &ge;70 mcg/dL should be considered for chelation regardless of trimester); consultation with experts in lead poisoning and high-risk pregnancy is recommended. Encephalopathic pregnant women should be chelated regardless of trimester (CDC, 2010). </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6165842\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if succimer is excreted in breast milk. When used for the treatment of lead poisoning, the amount of lead in breast milk may range from 0.6% to 3% of the maternal serum concentration. Women with confirmed blood lead levels &ge;40 mcg/dL should not initiate breast-feeding; pumping and discarding breast milk is recommended until blood lead levels are &lt;40 mcg/dL, at which point breast-feeding may resume (CDC, 2010). Calcium supplementation may reduce the amount of lead in breast milk.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F223354\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Blood lead levels (baseline and 7-21 days after completing chelation therapy); serum aminotransferase (baseline and weekly during treatment; may require more frequent monitoring in patients with a history of liver disease), CBC with differential and platelets (baseline, and weekly during treatment); hemoglobin or hematocrit, iron status, free erythrocyte protoporphyrin or zinc protoporphyrin; neurodevelopmental changes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F223345\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Succimer is an analog of dimercaprol. It forms water soluble chelates with heavy metals which are subsequently excreted renally. Succimer binds heavy metals; however, the chemical form of these chelates is not known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F223360\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: Rapid but incomplete</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: Primarily extracellular (Aposhian, 1992)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: &gt;95% primarily to albumin (Aposhian, 1992)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Rapidly and extensively to mixed succimer cysteine disulfides </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: ~3 hours (Aposhian, 1992) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak, serum: ~1-2 hours </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine (~25%) with peak urinary excretion between 2-4 hours (90% as mixed succimer-cysteine disulfide conjugates, 10% as unchanged drug); feces (as unabsorbed drug)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16323897\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsules</b> (Chemet Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg (100): $1,963.55</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6038833\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Chemet (AT, BB, BM);</li>\n      <li>Succicaptal (CH, FR, GR)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics Committee on Environmental Health. Lead exposure in children: prevention, detection, and management. <i>Pediatrics</i>. 2005;116(4):1036-1046.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dimercaptosuccinic-acid-succimer-drug-information/abstract-text/16199720/pubmed\" target=\"_blank\" id=\"16199720\">16199720</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Aposhian HV, Maiorino RM, Rivera M, et al, &ldquo;Human Studies With the Chelating Agents, DMPS and DMSA,&rdquo; <i>Clin Toxicol</i>, 1992, 30(4):505-28.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dimercaptosuccinic-acid-succimer-drug-information/abstract-text/1331491/pubmed\" target=\"_blank\" id=\"1331491\">1331491</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bradberry S and Vale A, &quot;Dimercaptosuccinic Acid (Succimer; DMSA) in Inorganic Lead Poisoning,&quot; <i>Clin Toxicol (Phila)</i>, 2009, 47(7):617-31.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dimercaptosuccinic-acid-succimer-drug-information/abstract-text/19663612/pubmed\" target=\"_blank\" id=\"19663612\">19663612</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control and Prevention (CDC), <i>Guidelines for the Identification and Management of Lead Exposure in Pregnant and Lactating Women</i>, Atlanta: CDC; 2010.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control and Prevention (CDC), <i>Managing Elevated Blood Lead Levels Among Young Children: Recommendations from the Advisory Committee on Childhood Lead Poisoning Prevention</i>, Atlanta: CDC; 2002.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control and Prevention (CDC), &ldquo;Interpreting and Managing Blood Lead Levels &lt;10 microg/dL in Children and Reducing Childhood Exposures to Lead: Recommendations of CDC's Advisory Committee on Childhood Lead Poisoning Prevention,&rdquo; <i>MMWR Recomm Rep</i>, 2007, 56(RR-8):1-16.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dimercaptosuccinic-acid-succimer-drug-information/abstract-text/17975528/pubmed\" target=\"_blank\" id=\"17975528\">17975528</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chemet (succimer) [prescribing information]. Lebanon, NJ: Recordati Rare Diseases Inc; April 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Crinnion WJ, &quot;EDTA Redistribution of Lead and Cadium into Soft Tissues in a Human With a High Lead Burden: Should DMSA Always be used to Follow EDTA in Such Cases?&quot; <i>Alt Med Rev</i>, 2011, 16(2):109-112.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dimercaptosuccinic-acid-succimer-drug-information/abstract-text/21649453/pubmed\" target=\"_blank\" id=\"21649453\">21649453</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dart RC, Hurlburt KM, Maiorino RM, et al, &ldquo;Pharmacokinetics of Meso-2,3-Dimercaptosuccinic Acid in Patients With Lead Poisoning and in Healthy Adults,&rdquo; <i>J Pediatr</i>, 1994, 125(2):309-16.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dimercaptosuccinic-acid-succimer-drug-information/abstract-text/8040783/pubmed\" target=\"_blank\" id=\"8040783\">8040783</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gardella C, &ldquo;Lead Exposure in Pregnancy: A Review of the Literature and Argument for Routine Prenatal Screening,&rdquo; <i>Obstet Gynecol Surv</i>, 2001, 56(4):231-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dimercaptosuccinic-acid-succimer-drug-information/abstract-text/11285436/pubmed\" target=\"_blank\" id=\"11285436\">11285436</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gracia RC and Snodgrass WR, &ldquo;Lead Toxicity and Chelation Therapy,&rdquo; <i>Am J Health Syst Pharm</i>, 2007, 64(1):45-53.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dimercaptosuccinic-acid-succimer-drug-information/abstract-text/17189579/pubmed\" target=\"_blank\" id=\"17189579\">17189579</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"17431500\"></a>Kosnett MJ, Wedeen RP, Rothenberg SJ, et al, &ldquo;Recommendations for Medical Management of Adult Lead Exposure,&rdquo; <i>Environ Health Perspect</i>, 2007, 115(3):463-71.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dimercaptosuccinic-acid-succimer-drug-information/abstract-text/17431500/pubmed\" target=\"_blank\" id=\"17431500\">17431500</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    &ldquo;Lead Exposure in Children: Prevention, Detection, and Management. American Academy of Pediatrics Committee on Environmental Health,&rdquo; <i>Pediatrics</i>, 2005, 116(4):1036-46.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dimercaptosuccinic-acid-succimer-drug-information/abstract-text/16199720/pubmed\" target=\"_blank\" id=\"16199720\">16199720</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9102 Version 85.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F223371\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F223372\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F223387\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F223374\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F223383\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F223375\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F223376\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F223377\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adjustment for Toxicity\" href=\"#F20989270\" class=\"outlineLink\">Dosing: Adjustment for Toxicity</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F223356\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F223342\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F5168980\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F223357\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F25470676\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F223348\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F223361\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F223346\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13300085\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F6223110\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F223352\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F6165840\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F6165842\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F223354\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F223345\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F223360\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16323897\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F6038833\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9102|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=dimercaptosuccinic-acid-succimer-patient-drug-information\" class=\"drug drug_patient\">Dimercaptosuccinic acid (succimer): Patient drug information</a></li><li><a href=\"topic.htm?path=dimercaptosuccinic-acid-succimer-pediatric-drug-information\" class=\"drug drug_pediatric\">Dimercaptosuccinic acid (succimer): Pediatric drug information</a></li></ul></div></div>","javascript":null}